All studies
AuthorisedHuman Pharmacology (Phase I)- OtherInterventional

An open-label, multicentric, phase 1 study to evaluate the safety, tolerability, and radiation dosimetry of endogenous radioligand therapy with (¹⁷⁷Lu)Lutetiumvipivotidtetraxetan in women with metastatic triple negative breast cancer (TNBC)

Triple negative breast cancer can be challenging to treat once it spreads, because standard hormone treatments do not work on it. This Phase 1 trial looks at a targeted treatment called radioligand therapy using a medicine named Pluvicto, alongside a special scanning agent called Locametz. Pluvicto works like a guided missile. It searches for a specific protein on cancer cells and attaches to them, delivering a small dose of radiation directly into the cancer while aiming to spare healthy tissues. Because this is an early-phase trial, the main goal is not yet to prove how well it cures cancer, but to check its safety. Researchers want to find out what side effects it causes, how well the body handles it, and how the radiation moves through body tissues. This information will help doctors decide if it should be studied in larger trials.

At a glance

Status
Authorised
Phase
Human Pharmacology (Phase I)- Other
Sponsor
Universitaetsklinikum Aachen AöR
Enrolment target
18
Start
14 Jul 2026

What is this study about?

Triple negative breast cancer is a form of breast cancer that does not have receptors for oestrogen, progesterone, or HER2. When this cancer spreads to other organs (known as metastatic cancer), finding effective treatments can be difficult. Researchers are looking for newer, smarter treatments that can target cancer cells without causing widespread harm to the rest of the body.

This trial investigates a treatment called radioligand therapy. It uses a drug called Pluvicto, which combines a targeting molecule with a radioactive particle. Before or during treatment, patients receive a scanning tracer called Locametz to see if their tumour cells carry the right docking points. If they do, Pluvicto can latch onto those cells and deliver targeted radiation from the inside to damage them.

Because this is a Phase 1 trial, doctors are testing this approach in a small group first. They need to understand the safest dose, what side effects occur, and how radiation passes through different organs like the kidneys and liver. The results will help researchers know if this can become a safe, viable option for women with advanced triple negative breast cancer in the future.

Key takeaways

  • Phase 1 study testing a targeted radiation drug called Pluvicto for advanced triple negative breast cancer.
  • Uses a special scan (Locametz) to check if your tumour has the right targets for the medicine.
  • Open to women aged 18 and over whose breast cancer has spread to other areas.
  • The main goals are to check safety, monitor side effects, and see where radiation travels in the body.
  • Taking part is completely voluntary, and you can withdraw at any time.

Who may be eligible?

This trial is designed for adult women aged 18 and over who have been diagnosed with metastatic triple negative breast cancer that has spread beyond the breast.

Before taking part, patients will have a specialised scan using a tracer called Locametz. This scan checks whether the cancer cells display the specific protein that the treatment needs to latch onto. If the scan shows the cancer has these targets, the patient may be able to proceed.

Patients must also have reasonably good kidney, liver, and bone marrow function so their bodies can handle the treatment safely. People who are pregnant, breastfeeding, or dealing with other severe medical conditions will not be able to join. Your oncology team can review the full list of medical requirements with you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am a woman aged 18 or older.
  2. I have been diagnosed with triple negative breast cancer.
  3. My cancer has spread to other parts of my body (metastatic).
  4. I am well enough to attend hospital visits for scans, blood tests, and infusions.
  5. I am willing to have a specialist scan to see if my cancer has the target protein.
Answer every question to see your result.

What does participation involve?

Taking part involves regular visits to a specialist hospital centre. First, you will undergo screening tests, including blood work, physical examinations, and special imaging scans using Locametz to ensure the trial is safe for you. If eligible, you will receive Pluvicto as an injection or slow drip into a vein. After each dose, you will have regular scans and blood tests to measure radiation levels and check your blood cells, kidneys, and liver. Because the medicine is mildly radioactive, the medical team will give you simple safety guidelines to follow for a few days after each dose, such as drinking plenty of fluids and keeping a short distance from young children or pregnant family members. Your care team will monitor you closely throughout the treatment and follow up with you for several months afterwards.

Potential risks and benefits

The main benefit of joining this study is helping researchers discover whether targeted radiation can help women with advanced triple negative breast cancer in the future. However, as an early-stage safety study, there is no guarantee that the treatment will shrink your tumour. There are risks of side effects, which may include tiredness, nausea, dry mouth, or a temporary drop in blood cell counts that could increase your risk of infection. Your study team will watch you carefully to manage any problems quickly. Taking part is completely voluntary, and you can withdraw from the study at any time without your regular NHS care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany

Common questions

Is this treatment the same as chemotherapy?

No. Chemotherapy travels all around the body to attack fast-growing cells. This treatment is a targeted radioligand therapy that aims to find specific cancer cells and deliver radiation directly to them.

Will I be radioactive to other people?

For a short time after treatment, small amounts of radiation leave your body through your urine. The hospital team will give you simple daily instructions to keep family members, especially children and pregnant women, completely safe.

Do I have to pay to take part in this trial?

No. The trial medicine, scans, and extra tests are provided free of charge, and some trials also help cover travel expenses.

Can I leave the study if I change my mind?

Yes. You have the right to leave the clinical trial at any point, and your standard cancer care will continue as normal.

Will this cure my breast cancer?

This is a Phase 1 safety trial, so doctors cannot promise it will cure your cancer. The main goal right now is to see if the drug is safe and tolerable.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.